The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo.

Among the Ebola viruses most species cause severe hemorrhagic fever in humans; however, Reston ebolavirus (REBOV) has not been associated with human disease despite numerous documented infections. While the molecular basis for this difference remains unclear, in vitro evidence has suggested a role f...

Full description

Bibliographic Details
Main Authors: Allison Groseth, Andrea Marzi, Thomas Hoenen, Astrid Herwig, Don Gardner, Stephan Becker, Hideki Ebihara, Heinz Feldmann
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS Pathogens
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22876185/pdf/?tool=EBI
id doaj-835ee4875e3c44228c2249d9b9ebd927
record_format Article
spelling doaj-835ee4875e3c44228c2249d9b9ebd9272021-04-21T17:27:18ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742012-01-0188e100284710.1371/journal.ppat.1002847The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo.Allison GrosethAndrea MarziThomas HoenenAstrid HerwigDon GardnerStephan BeckerHideki EbiharaHeinz FeldmannAmong the Ebola viruses most species cause severe hemorrhagic fever in humans; however, Reston ebolavirus (REBOV) has not been associated with human disease despite numerous documented infections. While the molecular basis for this difference remains unclear, in vitro evidence has suggested a role for the glycoprotein (GP) as a major filovirus pathogenicity factor, but direct evidence for such a role in the context of virus infection has been notably lacking. In order to assess the role of GP in EBOV virulence, we have developed a novel reverse genetics system for REBOV, which we report here. Together with a previously published full-length clone for Zaire ebolavirus (ZEBOV), this provides a unique possibility to directly investigate the role of an entire filovirus protein in pathogenesis. To this end we have generated recombinant ZEBOV (rZEBOV) and REBOV (rREBOV), as well as chimeric viruses in which the glycoproteins from these two virus species have been exchanged (rZEBOV-RGP and rREBOV-ZGP). All of these viruses could be rescued and the chimeras replicated with kinetics similar to their parent virus in tissue culture, indicating that the exchange of GP in these chimeric viruses is well tolerated. However, in a mouse model of infection rZEBOV-RGP demonstrated markedly decreased lethality and prolonged time to death when compared to rZEBOV, confirming that GP does indeed contribute to the full expression of virulence by ZEBOV. In contrast, rREBOV-ZGP did not show any signs of virulence, and was in fact slightly attenuated compared to rREBOV, demonstrating that GP alone is not sufficient to confer a lethal phenotype or exacerbate disease in this model. Thus, while these findings provide direct evidence that GP contributes to filovirus virulence in vivo, they also clearly indicate that other factors are needed for the acquisition of full virulence.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22876185/pdf/?tool=EBI
collection DOAJ
language English
format Article
sources DOAJ
author Allison Groseth
Andrea Marzi
Thomas Hoenen
Astrid Herwig
Don Gardner
Stephan Becker
Hideki Ebihara
Heinz Feldmann
spellingShingle Allison Groseth
Andrea Marzi
Thomas Hoenen
Astrid Herwig
Don Gardner
Stephan Becker
Hideki Ebihara
Heinz Feldmann
The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo.
PLoS Pathogens
author_facet Allison Groseth
Andrea Marzi
Thomas Hoenen
Astrid Herwig
Don Gardner
Stephan Becker
Hideki Ebihara
Heinz Feldmann
author_sort Allison Groseth
title The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo.
title_short The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo.
title_full The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo.
title_fullStr The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo.
title_full_unstemmed The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo.
title_sort ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo.
publisher Public Library of Science (PLoS)
series PLoS Pathogens
issn 1553-7366
1553-7374
publishDate 2012-01-01
description Among the Ebola viruses most species cause severe hemorrhagic fever in humans; however, Reston ebolavirus (REBOV) has not been associated with human disease despite numerous documented infections. While the molecular basis for this difference remains unclear, in vitro evidence has suggested a role for the glycoprotein (GP) as a major filovirus pathogenicity factor, but direct evidence for such a role in the context of virus infection has been notably lacking. In order to assess the role of GP in EBOV virulence, we have developed a novel reverse genetics system for REBOV, which we report here. Together with a previously published full-length clone for Zaire ebolavirus (ZEBOV), this provides a unique possibility to directly investigate the role of an entire filovirus protein in pathogenesis. To this end we have generated recombinant ZEBOV (rZEBOV) and REBOV (rREBOV), as well as chimeric viruses in which the glycoproteins from these two virus species have been exchanged (rZEBOV-RGP and rREBOV-ZGP). All of these viruses could be rescued and the chimeras replicated with kinetics similar to their parent virus in tissue culture, indicating that the exchange of GP in these chimeric viruses is well tolerated. However, in a mouse model of infection rZEBOV-RGP demonstrated markedly decreased lethality and prolonged time to death when compared to rZEBOV, confirming that GP does indeed contribute to the full expression of virulence by ZEBOV. In contrast, rREBOV-ZGP did not show any signs of virulence, and was in fact slightly attenuated compared to rREBOV, demonstrating that GP alone is not sufficient to confer a lethal phenotype or exacerbate disease in this model. Thus, while these findings provide direct evidence that GP contributes to filovirus virulence in vivo, they also clearly indicate that other factors are needed for the acquisition of full virulence.
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22876185/pdf/?tool=EBI
work_keys_str_mv AT allisongroseth theebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo
AT andreamarzi theebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo
AT thomashoenen theebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo
AT astridherwig theebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo
AT dongardner theebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo
AT stephanbecker theebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo
AT hidekiebihara theebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo
AT heinzfeldmann theebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo
AT allisongroseth ebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo
AT andreamarzi ebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo
AT thomashoenen ebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo
AT astridherwig ebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo
AT dongardner ebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo
AT stephanbecker ebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo
AT hidekiebihara ebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo
AT heinzfeldmann ebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo
_version_ 1714666167178625024